2022 PepTalk Keynote Presentations:
Merging MOA, Structural Information & Single Cell Screening to Identify Potent mABs as Potential Therapeutic Candidates
John Williams, PhD, Professor of Molecular Medicine and Co-Director, Drug Discovery and Structural Biology Core, Beckman Research Institute at City
of Hope
CDR Swapping and Multivalency Protein Engineering Approaches for Generating Broadly Neutralizing Nanobodies against SARS-CoV-2
Peter M. Tessier, PhD, Albert M. Mattocks Professor, Pharmaceutical Sciences & Chemical Engineering, University of Michigan
Developability of Bispecific Antibodies
Paul Parren, PhD, Executive Vice President, Lava Therapeutics; Professor, Leiden University Medical Center
Trispecific Antibodies – Taking the Concept of Multi-Targeting One Step Further
Ercole Rao, PhD, Group Leader Biologics Research, Engineered Protein Therapeutics, Sanofi Germany GmbH
Chimeric Antigen Receptor-Modified Immune Effector Cell Therapies: Learning from the Present; Charting a Path to the Future
Renier J. Brentjens, PhD, Director, Cellular Therapeutics, Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center
A Systematic Approach to Evaluating Closed System Transfer Devices (CSTDs) During Drug Product Process Development
Sanket Patke, PhD, Associate Director, Sanofi
Novel Degradation Mechanisms of Polysorbate: Complex Reaction Pathways of a Complex Surfactant
Christian Schoeneich, PhD, Takeru Higuchi Distinguished Professor & Chair, Pharmaceutical Chemistry, University of Kansas Lawrence
Requirements for Particulates in the European Pharmacopeia
Hanns-Christian Mahler, PhD, Board Member, Bionter AG
Non-Radioactive Assays for Cell Therapies
Preet M. Chaudhary, MD, PhD, Professor & Chief Hematology & Director, Blood & Marrow Transplant, University of Southern California
Nucleic Acids as Household Medicine: Living in the World of RNA Therapeutics
Mano Manoharan, PhD, Distinguished Scientist & Senior Vice President, Innovation Chemistry, Alnylam Pharmaceuticals
Cell Engineering Efficiency and Quality
Zhimei Du, PhD, Director, Biologics & Cell Therapeutics Process Development, Merck and Co., Inc.
Lessons Learned from Expression Liabilities in a Four-Chain Bispecific
Rene Hubert, PhD, Director, Biologics Optimization, Amgen Inc.
Advances in High-Throughput Protein Purification at Different Scales
John K. Kawooya, PhD, Director, Biologics Optimization and Therapeutic Discovery, Amgen Inc.
High Performance Countercurrent Membrane Purification (HPCMP) for Continuous Downstream Processing
Andrew Zydney, PhD, Bayard D. Kunkle Chair & Professor, Chemical Engineering, Pennsylvania State University